JP2013534425A5 - - Google Patents

Download PDF

Info

Publication number
JP2013534425A5
JP2013534425A5 JP2013518762A JP2013518762A JP2013534425A5 JP 2013534425 A5 JP2013534425 A5 JP 2013534425A5 JP 2013518762 A JP2013518762 A JP 2013518762A JP 2013518762 A JP2013518762 A JP 2013518762A JP 2013534425 A5 JP2013534425 A5 JP 2013534425A5
Authority
JP
Japan
Prior art keywords
nucleotides
strand
less
dsrna
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518762A
Other languages
English (en)
Japanese (ja)
Other versions
JP5976643B2 (ja
JP2013534425A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042820 external-priority patent/WO2012006243A2/en
Publication of JP2013534425A publication Critical patent/JP2013534425A/ja
Publication of JP2013534425A5 publication Critical patent/JP2013534425A5/ja
Application granted granted Critical
Publication of JP5976643B2 publication Critical patent/JP5976643B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518762A 2010-07-06 2011-07-01 二本鎖rnaによるベータ−カテニンの特異的阻害に対する方法と組成物 Expired - Fee Related JP5976643B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36177610P 2010-07-06 2010-07-06
US61/361,776 2010-07-06
PCT/US2011/042820 WO2012006243A2 (en) 2010-07-06 2011-07-01 Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna

Publications (3)

Publication Number Publication Date
JP2013534425A JP2013534425A (ja) 2013-09-05
JP2013534425A5 true JP2013534425A5 (cg-RX-API-DMAC7.html) 2014-08-14
JP5976643B2 JP5976643B2 (ja) 2016-08-24

Family

ID=45441761

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518762A Expired - Fee Related JP5976643B2 (ja) 2010-07-06 2011-07-01 二本鎖rnaによるベータ−カテニンの特異的阻害に対する方法と組成物

Country Status (9)

Country Link
US (5) US8815825B2 (cg-RX-API-DMAC7.html)
EP (4) EP3854874A1 (cg-RX-API-DMAC7.html)
JP (1) JP5976643B2 (cg-RX-API-DMAC7.html)
AU (1) AU2011276365B2 (cg-RX-API-DMAC7.html)
CA (2) CA2804214C (cg-RX-API-DMAC7.html)
DK (3) DK2591105T3 (cg-RX-API-DMAC7.html)
ES (3) ES2734743T3 (cg-RX-API-DMAC7.html)
PT (1) PT3587579T (cg-RX-API-DMAC7.html)
WO (1) WO2012006243A2 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112014016870A2 (pt) 2012-01-09 2017-06-27 Huesken Dieter composições orgânicas para tratar doenças relacionadas com beta-catenina
CA2978450A1 (en) * 2015-03-04 2016-09-09 The University Of Chicago Beta-catenin inhibitors in cancer immunotherapy
AU2017232496B2 (en) 2016-03-16 2022-11-24 Dicerna Pharmaceuticals, Inc. Compositions and methods for the treatment of a beta-catenin-associated disease or disorder
WO2017173297A1 (en) 2016-04-01 2017-10-05 Avidity Biosciences Llc Beta-catenin nucleic acids and uses thereof
US20180193270A1 (en) 2016-11-29 2018-07-12 PureTech Health LLC Exosomes for delivery of therapeutic agents
KR20190128692A (ko) * 2017-03-28 2019-11-18 다이서나 파마수이티컬, 인크. 면역요법을 강화시키기 위한 베타-카테닌 발현의 감소
US10407681B2 (en) * 2017-03-28 2019-09-10 The United States Of America, As Represented By The Secretary Of Agriculture Plant-mediated silencing of a fatty acid and retinoid binding protein in Pratylenchus penetrans
JP2021500026A (ja) * 2017-10-18 2021-01-07 ディセルナ ファーマシューティカルズ インコーポレイテッド βカテニン核酸阻害剤分子
WO2019100039A1 (en) * 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
AU2019205904A1 (en) 2018-01-05 2020-06-18 Dicerna Pharmaceuticals, Inc. Reducing beta-catenin and IDO expression to potentiate immunotherapy
EP3740248A4 (en) 2018-03-02 2022-01-26 Dicerna Pharmaceuticals, Inc. Methods and compositions for treating bile duct paucity-associated conditions
US10961534B2 (en) 2018-07-13 2021-03-30 University of Pittsburgh—of the Commonwealth System of Higher Education Methods of treating porphyria
US20240392297A1 (en) * 2020-12-23 2024-11-28 Eli Lilly And Company Rna therapeutics and methods of use thereof
TW202325312A (zh) * 2021-07-23 2023-07-01 美商艾拉倫製藥股份有限公司 β-鏈蛋白(CTNNB1)iRNA組成物及其使用方法
WO2026032257A1 (zh) * 2024-08-05 2026-02-12 上海拓界生物医药科技有限公司 靶向CTNNB1的RNAi剂及其医药用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
AU649074B2 (en) 1990-10-12 1994-05-12 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US5652094A (en) 1992-01-31 1997-07-29 University Of Montreal Nucleozymes
US6326487B1 (en) 1995-06-05 2001-12-04 Aventis Pharma Deutschland Gmbh 3 modified oligonucleotide derivatives
US6218108B1 (en) 1997-05-16 2001-04-17 Research Corporation Technologies, Inc. Nucleoside analogs with polycyclic aromatic groups attached, methods of synthesis and uses therefor
US6248878B1 (en) 1996-12-24 2001-06-19 Ribozyme Pharmaceuticals, Inc. Nucleoside analogs
US7829693B2 (en) * 1999-11-24 2010-11-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of a target gene
US8273866B2 (en) 2002-02-20 2012-09-25 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SINA)
US20030064384A1 (en) * 2001-04-02 2003-04-03 Mien-Chie Hung Beta-catenin is a strong and independent prognostic factor for cancer
US20060019917A1 (en) * 2001-05-18 2006-01-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
JP4912873B2 (ja) * 2003-04-09 2012-04-11 アルナイラム ファーマシューティカルズ, インコーポレイテッド iRNA複合体
WO2004091515A2 (en) 2003-04-09 2004-10-28 Alnylam Pharmaceuticals, Inc. iRNA CONJUGATES
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
CA2566286A1 (en) * 2004-05-11 2005-12-08 Rnai Co., Ltd. Polynucleotide causing rna interfere and method of regulating gene expression with the use of the same
US20080213891A1 (en) 2004-07-21 2008-09-04 Alnylam Pharmaceuticals, Inc. RNAi Agents Comprising Universal Nucleobases
WO2006031977A2 (en) * 2004-09-13 2006-03-23 The Regents Of The University Of California Inhibition of pancreatic cancer cell growth
US20090176725A1 (en) * 2005-08-17 2009-07-09 Sirna Therapeutics Inc. Chemically modified short interfering nucleic acid molecules that mediate rna interference
WO2007030167A1 (en) 2005-09-02 2007-03-15 Nastech Pharmaceutical Company Inc. Modification of double-stranded ribonucleic acid molecules
WO2007031091A2 (en) * 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
WO2008109369A2 (en) * 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
DK2152879T3 (da) * 2007-05-01 2013-02-18 Santaris Pharma As RNA antagonistforbindelser til modulering af beta-catenin
EP2173875B1 (en) * 2007-06-15 2017-08-30 Cequent Pharmaceuticals, Inc. Bacteria mediated gene silencing
TWI455944B (zh) * 2008-07-01 2014-10-11 Daiichi Sankyo Co Ltd 雙股多核苷酸
JP2012005734A (ja) 2010-06-28 2012-01-12 Panasonic Corp 電気掃除機用吸込具及びそれを備えた電気掃除機
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸(siNA)的RNA干扰介导的联蛋白(钙粘蛋白关联蛋白质),β1(CTNNB1)基因表达的抑制

Similar Documents

Publication Publication Date Title
JP2013534424A5 (cg-RX-API-DMAC7.html)
JP7307137B2 (ja) GST-π遺伝子を調節するためのRNA干渉剤
KR101166214B1 (ko) 아이지에프비피-2 및 아이지에프비피-5를 억제하는 양특이성 안티센스 올리고뉴클레오티드 및 그 사용방법
JP2022159552A (ja) iNOS阻害組成物および乳がん治療薬としてのその使用
JP2007529224A5 (cg-RX-API-DMAC7.html)
RU2013148024A (ru) Композиции и способы ингибирования экспрессии гена tmprss6
SG170780A1 (en) Compositions and methods for inhibiting expression of eg5 gene
CN107177598A (zh) 用于抑制BIRC5靶基因mRNA表达的寡核酸分子及其成套组合物
CN102719432B (zh) 特异性抑制肿瘤凋亡抑制基因Bcl2的双链不对称小核酸干扰分子asiRNA及其应用
WO2017068790A1 (ja) 核酸複合体
JP2022031642A (ja) アンチセンスオリゴヌクレオチド
US8193333B2 (en) Cancer therapy using Bcl-Xl-specific siNA
EP3452593A1 (en) The incrna meg3 for therapy and diagnosis of cardiac remodelling
JP2007530431A5 (cg-RX-API-DMAC7.html)
WO2025016342A1 (zh) 靶向血管紧张素原的寡核苷酸及其用途
EP2064328B1 (en) Sensitization of cancer cells to therapy using sina targeting genes from the 1p and 19q chromosomal regions
KR101993377B1 (ko) Bcl2 유전자 및 bi-1 유전자의 발현을 동시에 억제하는 핵산
CN118510894A (zh) 用于抑制前激肽释放酶(pkk)蛋白表达的组合物和方法
CA3227144A1 (en) Modified small interfering rna molecules with reduced off-target effects
EP3680334A1 (en) Double-stranded rna molecule targeting ckip-1 and use thereof
CN101173275B (zh) 抑制sars冠状病毒m蛋白基因表达的小干扰rna及其编码基因与应用
Li et al. Engineered pistol ribozymes selectively target KRAS G12V with enhanced efficacy by capping modification
CN120519453A (zh) 一种靶向FASN基因的siRNA、载体复合物及其应用
WO2023159138A2 (en) Use of dinucleotide repeat rnas to treat cancer
WO2024154163A1 (en) Product comprising an aptamer conjugated to the edited mirna mir-589-3p and medical uses thereof